SI
SLNO

Sofinnova Investments’s Soleno Therapeutics SLNO Stock Holding History

Sofinnova Investments’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-529,300
Closed -$37.8M – 77
2025
Q1 		$37.8M Buy
+529,300
New +$25.8M 2.47% 12
2024
Q4 		– Sell
-300,000
Closed -$15.1M – 75
2024
Q3 		$15.1M Buy
+300,000
New +$14.4M 1.2% 22

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Sofinnova Investments's SLNO Position: Q1 2026 in Review

Sofinnova Investments increased its Soleno Therapeutics (SLNO) stake by 18% in Q1 2026, buying an estimated $89.2K and bringing the position to 14,689 shares worth $492K. The position accounts for 0.02% of the portfolio, ranked #72.

Sofinnova Investments first reported a position in SLNO in Q4 2023 and has held it in 10 quarters since. The position peaked at $34.8M in Q2 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Sofinnova Investments held 14,689 shares of Soleno Therapeutics worth $492K as of Q1 2026.
  • Sofinnova Investments bought 2,275 Soleno Therapeutics shares in Q1 2026, an estimated $89.2K.
  • Soleno Therapeutics made up 0.02% of Sofinnova Investments's portfolio in Q1 2026, its #72 holding.
  • Sofinnova Investments first reported a position in Soleno Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Sofinnova Investments's Soleno Therapeutics position peaked at $34.8M in Q2 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.